These differences in the pharmacodynamic profile do not seem to be relevant for improving the cognitive deficit in the Fmr1 KO mouse model, since both rimonabant and NESS0327 showed similar beneficial effects. The gene discussed is FMR1; the disease is Cognitive impairment.